Research programme: anticancer therapeutics - Amgen
Alternative Names: Anticancer therapeutics research programme - AmgenLatest Information Update: 17 Jul 2014
At a glance
- Originator Amgen
- Developer Amgen; EPIRUS Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Jul 2014 No development reported - Preclinical for Cancer in USA (unspecified route)
- 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
- 08 Sep 2008 Preclinical development is ongoing in USA